Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

New date for Sectra’s nine-month interim report 2017/2018

Linköping, Sweden – November 1, 2017 – The Board of Directors of international medical imaging IT and cybersecurity company Sectra  (SECT-B.ST) has decided to change the publication date of the company’s nine-month interim report for the 2017/2018 fiscal year. The new date is Monday, March 12, 2018, at 8:00 a.m. (previous planned publication date was March 6, 2018).The change was made due to the fact that the original report date coincides with important industry trade fairs that management need to attend.  Sectra’s financial reporting calendar

ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL

1 November 2017 07:00 GMT ASTRAZENECA AND ASPEN COMPLETE AGREEMENT FORRESIDUAL RIGHTS TO ANAESTHETIC MEDICINES AstraZeneca today announced that it has completed the commercialisation agreement  (announced 14 September 2017) with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/

KONE a top climate change performer with an A- score in CDP 2017

KONE Corporation, trade press release, November 1, 2017 KONE, a global leader in the elevator and escalator industry, has been recognized for its actions and strategies in response to climate change. The company has received a score of A- on climate action and is in the top category for advancing environmental stewardship. The score ranges from A to D, with A the best possible rating, and is based on independent assessment against the scoring criteria of CDP, an international not-for-profit organization that drives sustainable economies. KONE is proud to have reported in CDP

Record-breaking cruise season in Copenhagen

The cruise season was a successful one for Copenhagen Malmö Port, CMP. Copenhagen welcomed 850,000 passengers, setting a new record. CMP is now investing in continued growth. A new terminal is being built in Copenhagen, and as from April 2018 Visby will form part of CMP’s cruise operations.Cruise operations continue to have the wind in their sails. As the figures for 2017 are added up, CMP has welcomed 325 ships and 850,000 passengers to Copenhagen. This is a new passenger record, which is partly the result of the ships becoming bigger and bigger. “Last season we welcomed 15 larger ships,

AstraZeneca tralokinumab update in severe asthma

This announcement contains inside information 1 November 2017 07:00 GMT ASTRAZENECA PROVIDES UPDATE ON TRALOKINUMAB PHASE III PROGRAMME IN SEVERE, UNCONTROLLED ASTHMA AstraZeneca and its global biologics research and development arm, MedImmune, today announced the top-line results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, in severe, uncontrolled asthma. In STRATOS 2, tralokinumab did not achieve a statistically-significant reduction in the annual asthma exacerbation rate (AAER), the primary endpoint,

Skanska builds replacement schools in Cincinnati, USA, for USD 65M, about SEK 560M

Skanska has, in a joint venture with Megen Construction, signed a contract with the Winton Woods City School District and the Ohio Facilities Construction Commission to manage a multi-building construction project in Cincinnati, Ohio, USA. The total contract is worth USD 93M. Skanska will include its 70 percent share of the contract worth USD 65M, about  SEK 560M, in the US order bookings for the fourth quarter 2017.The project includes two new replacement schools: a 19,000-square-meter, elementary school, and a 22,000-square-meter middle and high school. Both projects will seek a minimum

As is society, so is the apartment building

YIT Corporation News, November 1, 2017 at 09:00 a.m.The history of apartment buildings in independent Finland is a tale of social change. Equal rights, urbanisation, economic fluctuations and the rise of environmentalism are all visible in the buildings of their time. The 1880s saw the rise of the first apartment buildings in the Finland´s largest cities.  The construction of apartment buildings underwent several changes in early 20th century, during the time Finland sought and claimed its independence. In the early 1900s, reinforced concrete revolutionised the industry and

Vicore Pharma to Attend Two Investor Conferences in London in November 2017

Vicore Pharma will present at the Biotech and Money Inv€$tival Showcase in partnership with Jefferies and host one-to-one meetings at the Jefferies 2017 London Healthcare ConferenceVicore Pharma Holding (publ) (ticker:VICO), announced today that its CEO, Per Jansson, is scheduled to present at the Biotech and Money Inv€$tival showcase on Tuesday, November 14, 2017, at the Waldorf Hilton Hotel in London, UK at 1:45 p.m. GMT and will attend the Jefferies 2017 London Healthcare Conference, November 15-16, 2017, also at the Waldorf Hilton Hotel in London. Vicore Pharma’s CEO, Per Jansson,

Stora Enso to divest Puumerkki, a wholesaler of wooden building materials

STORA ENSO OYJ INVESTOR NEWS 1 November 2017 at 9.00 EETStora Enso has divested 100% of its shares in the Finnish Puumerkki Oy and the Estonian Puumerkki AS to Mimir Invest AB, a global investment firm. Puumerkki is a specialised wholesaler of wooden building materials and was 100% owned by Stora Enso. This divestment supports Stora Enso’s Wood Products division in focusing on its growth strategy and further build on the strength of the premium portfolio of products and services. Puumerkki’s wholesale business does not belong to Stora Enso’s core business. The new owner is in a better

PRESS RELEASE: VTT to develop new enzymes found in India’s wildfire-prone areas for biorefineries

Micro-organisms found in the wildfire-prone rainforests of India are an exciting prospect for biochemical production, as they are accustomed to the challenging conditions following a forest fire. The enzymes they produce are likely to also have a higher-than-normal resistance to the substances released from biomass in high-temperature industrial processes. An EU and nationally funded project led by VTT Technical Research Centre of Finland, called IndZyme, is looking to study whether they are capable of breaking down agricultural waste better than commercial enzymes. Converting the

Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017

Interim report forEnzymatica AB (publ)                                                                                                                                                                             January-September 2017Sales soar in third quarter Q3              · Net sales reached SEK 24.8 (11.9) million. · Loss after tax came in at SEK -3.6 (-6.5) million. · Earnings per share, basic and diluted, were SEK -0.04 (-0.08). · Cash and cash equivalents were SEK 9.5 (49.9) million. Significant events in Q3 · German STADA's order from Q2 for SEK 12

Hexagon Composites ASA: Results for the third quarter 2017

In the third quarter 2017 Hexagon Composites generated NOK 352.8 (266.2) million in operating income and made an operating profit before depreciation and amortization (EBITDA) of NOK 51.2 (4.6) million. Operating profit (EBIT) was NOK 33.8 (-12.4) million and profit before tax came to NOK 21.8 (-18.4) million. Overall, Group operating profit has markedly improved versus the third quarter 2016, and the previous quarter. Operating results in the third quarter were impacted positively by a 32% growth in revenues versus the same period last year. Both the Low-Pressure and High-Pressure

Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type

Valby, Denmark and Tokyo, Japan, 1 November 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce that the two companies will initiate a third clinical phase III study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type. The trial is expected to commence during the first half of 2018.  The decision to initiate a third trial follows discussions with the U.S. Food and Drug Administration (FDA) in October regarding the two, completed phase III clinical trials for the agitation indication that were completed by

Nokian Tyres plc Interim Report January–September 2017: Strong performance with solid full year expectations

Nokian Tyres plc Interim Report January–September 2017, November 1, 2017, 8:00 a.m. This release is a summary of Nokian Tyres’ Interim Report January–September 2017. The complete report is attached to this release. It is also available on the company website at www.nokiantyres.com/company/investors/. July–September 2017 · Net sales increased by 14.5% to EUR 363.1 million (317.2 in 7–9/2016). Currency exchange rate changes affected net sales negatively by EUR 0.2 million compared with the rates in 7–9/2016. · Operating profit increased by 21.3% to EUR 89.8 million (74.1).

Nokian Tyres’ financial calendar and Annual General Meeting in 2018

Nokian Tyres plc Financial calendar November 1, 2017, 8.00 a.m.During the year 2018, Nokian Tyres plc will publish the year 2017 Financial Statement Bulletin, two Interim Reports and one Half Year Financial Report as follows: Financial Statement Bulletin 2017, February 2, 2018 Interim Report for January–March 2018, May 9, 2018 Half Year Financial Report for January–June 2018, August 8, 2018 Interim Report for January–September 2018, October 31, 2018 The 2017 Annual Report will be available on Nokian Tyres home pages, https://www.nokiantyres.com/company/publications/annual-

Multiconsult ASA – Repurchase of own shares

On 31 October 2017, Multiconsult ASA ("Multiconsult") purchased 1 027 of its own shares at an average price of NOK 86.11 per share. The shares were purchased in accordance with the Company's share repurchase programme as announced on 22 September 2017. The shares were acquired on Oslo Børs.Following this transaction Multiconsult holds 103 877 of its own shares.  For further information, please contact: Investor relations:       Mirza Koristovic, Head of Investor Relations      Phone: +47 93 87 05 25      E-mail: ir@multiconsult.no Media:      Gaute Christensen, VP

Third Quarter 2017 Report,Year on Year Revenue Growth and Second Acquisition Completed

Cognosec AB (Publ) (“Cognosec” or the “Group”) announces today its third quarter interim report for 2017, which can be found here .Total year to date revenues grew 4.8% to 10.9m EUR (Q3 YTD 2016: 10.3m EUR). This, combined with a lower cost of sales, demonstrated improved margins compared to the third quarter of 2016.  Total Gross Profit for Q3 2017 increased 5.6% from 1.2m EUR (Q3 2016) to 1.3m EUR (Q3 2017). There were a number of key contracts that did not close in time for Q3 in Africa and the Middle East and it is our and our clients’ intent

Allianz Worldwide Partners Donates to Local and National Charities

Henrico-based Allianz Worldwide Partners USA has donated $44,000 to local and national charities.  The company matched employee hurricane relief contributions to the American Red Cross and supported events that benefited the Cystic Fibrosis Foundation and Richmond-based Safe Harbor. The company and its employees donated almost $14,000 to the American Red Cross to be earmarked for hurricane relief in the wake of devastating hurricanes Harvey, Irma and Maria.  The American Red Cross is using these donations to provide shelter, food, comfort and emergency support for individuals and

New number of shares in Balco Group AB

In October, the number of shares and voting rights in respect of Balco Group AB has changed due to the redemption of all preference shares, alterations to the articles of association and issue of new shares (directed debt to equity swap of new shares) in conjunction with the initial public offering of Balco's on Nasdaq Stockholm Stock Exchange. The number of shares and votes in Balco Group AB has increased by 10,139,984 shares in total. Following the increase, the total number of shares and votes in Balco is 21,428,773 shares and votes. Following the increase, the share capital amounts

Change in the number of shares and votes in BioArctic AB (publ)

Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has increased during the month of October due to the new share issue carried out in connection with the listing of BioArctic’s B-share on Nasdaq Stockholm. A total of 25,000,000 B-shares have been added. At October 31, 2017 the number of A-shares, each representing ten (10) votes, amounts to 14,399,996 and the number of B-shares, each representing one (1) vote, amounts to 73,659,989. The total number of votes thus amounts to 217,659,

The Nuance Group (Sverige) AB awarded service concession contract with airport group Swedavia AB

The Nuance Group (Sverige) AB has been awarded a new service concession contract with Swedavia AB to run tax- and duty-free operations at Swedavia’s ten airports. The contract will run for seven years, with the option of a three-year extension. The value of retail sales is estimated to be about SEK 8,000-10,000 M for the first seven years. The Nuance Group (Sverige) AB is part of Dufry AG, which is a leading global travel retailer with more than 2,200 duty-free and duty-paid shops located at airports, on cruise liners, in seaports, in railway stations, hotels and downtown. The group

Increase in share capital and number of shares in Immunovia

The share capital and number of shares in Immunovia AB (publ) has changed due to share warrants being exercised in the company. ·          The share capital has increased from SEK 840,902.95 to SEK 865,902.95. ·          The number of shares has increased by 514,000 to 17,318,059 shares. ·          The dilution amounts to 3.1%.The share warrants that have been exercised are in part constituted of Immunovia’s incentive program for senior management according to decisions taken at the 2014 and 2015 AGM’s, issued the respective years.

There are no items matching the current filter
There are no more items matching the current filter
Back to top